Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basimglurant MAD Safety and PK Study
NCT02433093Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of basimglurant in major depressive disorder (MDD) (7 arms), sponsored by Roche. Primary endpoints: Incidence of adverse events up to 10 weeks, Suicidality as assessed using the Columbia Suicide Severity Rating Scale (C-SSRS) up to 10 weeks and 1 more. Started Apr 2015; status: completed.
02
Drugs
basimglurant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02433093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02433093.